26 results
6-K
EX-99.2
CNTB
Connect Biopharma Holdings Ltd
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
of RMB 942.5 million (USD 145.9 million), offset by certain adjustments of RMB 695.8 million (USD 107.7 million) and negative working capital change … deductible value-added tax, or VAT, balances which can offset against future VAT payables and a decrease in other payables and accruals of RMB 1.6 million
6-K
CNTB
Connect Biopharma Holdings Ltd
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
for RMB 4.0 million, offset by depreciation of RMB 1.5 million.
Cash and Cash Equivalents
The balance of cash and cash equivalents decreased from RMB … activities was RMB 342.5 million (USD 51.0 million), primarily due to our net loss of RMB 401.3 million (USD 59.8 million), offset by adjustments of RMB
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
23 Jun 23
House Lease Contract
4:31pm
for using the deposit to offset the rent, enterprise management service fee, utilities and other expenses payable shall be made. After receiving … withhold part or all of the deposit to offset the economic losses suffered by Party A or the third party;
(2)Party B’s lease must comply
6-K
CNTB
Connect Biopharma Holdings Ltd
12 Sep 23
Connect Biopharma Reports First Half 2023 Financial Results and Provides Business Update
4:47pm
of RMB 211.5 million (USD 29.3 million), offset by adjustments of RMB 7.9 million (USD 1.1 million) and negative working capital change in our operating … -current assets of RMB 3.6 million (USD 0.5 million) due to deductible value-added tax ("VAT") which can offset against future VAT payables, a decrease
6-K
EX-99.2
CNTB
Connect Biopharma Holdings Ltd
3 Jun 21
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
6:04am
onset and offset of action ‒ Greater clinical response S1P1 Sphingosine 1-phosphate-receptor 1 ‒ Safety profile consistent with second generation S1P1 1 … in both UC & CD for optimal effects Potential for clinical results to show ‒ Once daily dosing, with fast onset and offset of action ‒ Greater clinical
6-K
EX-99.1
1rectjwol5du4
16 Apr 24
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
4:20pm
20-F
EX-4.13
egw 7v5p4pmj1
31 Mar 22
Annual report (foreign)
4:33pm
F-1
EX-10.11
keszk
26 Feb 21
Registration statement (foreign)
4:56pm
F-1/A
ls5 vulabxm8f
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
F-1
v6lc6 izhjx
26 Feb 21
Registration statement (foreign)
4:56pm
DRS
gjmdvjc6u4kq
17 Dec 20
Draft registration statement
12:00am
424B4
jjuk23mxs517ll
19 Mar 21
Prospectus supplement with pricing info
4:49pm
F-1/A
5vzgag
18 Mar 21
Registration statement (foreign) (amended)
6:15am
DRS/A
b6z7iok0
26 Jan 21
Draft registration statement (amended)
12:00am
20-F
92d90 ob2cfheiy78g5p
31 Mar 22
Annual report (foreign)
4:33pm
F-1
EX-10.1
xhi4gy1pk50p
26 Feb 21
Registration statement (foreign)
4:56pm
DRS
EX-10.1
svme1w2d
17 Dec 20
Draft registration statement
12:00am